Fresenius wins record low yield, but has to widen price on seven year

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Fresenius wins record low yield, but has to widen price on seven year

Sometimes it is difficult to live between two worlds. Fresenius, the Ba1/BB+ rated German healthcare business, is a speculative grade issuer, but prices so tight it could be investment grade.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Related articles

Gift this article